Antiaging Vaccines Targeting Senescent Cells
Authors:
- 15 February 2022
- journal article
- research article
- Published by SAGE Publications in Rejuvenation Research
- Vol. 25 (1) , 39-45
Abstract
The development of senomorphic drugs to attenuate the senescent phenotype and senolytics to clear pro-inflammatory senescent cells (SCs) to treat aging-associated disorders is being hotly pursued. The effort is complicated by the fact that SCs play a constructive role in some cellular processes such as tissue repair and wound healing. However, concerns about efficacy, which SCs to target, and unwanted side effects have created potential roadblocks. Chimeric antigen receptor T cells directed against urokinase-type plasminogen activator receptor, which is expressed on at least a subset of SCs in atherosclerotic plaques and fibrotic livers, removed SC and improved glucose metabolism. A vaccine targeting CD153-expressing senescent T cells also improved glucose metabolism in obese mice. Recent work to selectively target SCs associated with several pathologies has resulted in the creation of a peptide vaccine that primarily targets endothelial cells expressing high levels of GPNMB, recently identified as a biomarker of senescence. The vaccine reduces atherosclerotic plaque burden and metabolic dysfunction such as glucose intolerance in mouse models of obesity and atherosclerosis. For translation to humans the activity of the vaccine will need to be tightly controlled, as the target GPNMB has multiple roles in normal physiology, including acting to inhibit and possibly resolve inflammation. A promising alternative approach would be to use passive immunization with a monoclonal antibody directed against GPNMB.Keywords
This publication has 53 references indexed in Scilit:
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast CancerJournal of Clinical Oncology, 2015
- The Achilles’ heel of senescent cells: from transcriptome to senolytic drugsAging Cell, 2015
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced MelanomaJournal of Clinical Oncology, 2014
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast CancerJournal of Clinical Oncology, 2014
- Direct Binding of Bcl-2 Family Proteins by Quercetin Triggers Its Pro-Apoptotic ActivityACS Chemical Biology, 2014
- Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in cerebral ischemia–reperfusion injuryNeuroscience, 2014
- Mesenchymal markers on human adipose stem/progenitor cellsCytometry Part A, 2012
- DC-HIL/Glycoprotein Nmb Promotes Growth of Melanoma in Mice by Inhibiting the Activation of Tumor-Reactive T CellsCancer Research, 2010
- The DC‐HIL/syndecan‐4 pathway inhibits human allogeneic T‐cell responsesEuropean Journal of Immunology, 2009
- Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriersNeurology, 2006